New antihypertensive drugs under development

Current Medicinal Chemistry

Volumn 22, Issue 3, 2015, Pages 305-342

  Tamargo, J ^a   Duarte, J ^b   Ruilope, L M ^c  

^a SCHOOL OF MEDICINE   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Antihypertensives; Calcium and potassium channel blockers; Hypertension; Renelase; Renin angiotensin aldosterone system inhibitors; Vasopeptidase inhibitors

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR AGONIST; ANGIOTENSIN[1-7]; ANTIHYPERTENSIVE AGENT; BR 4628; CALCIUM CHANNEL BLOCKING AGENT; CHYMASE INHIBITOR; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FINERENONE; GUANYLATE CYCLASE ACTIVATOR; HYDROGEN SULFIDE; ILEPATRIL; LOSARTAN; MINERALOCORTICOID ANTAGONIST; NATRIURETIC FACTOR; NITROGEN OXIDE; OMAPATRILAT; OSILODROSTAT; OXIDOREDUCTASE INHIBITOR; PMD 3117; POTASSIUM CHANNEL STIMULATING AGENT; RENIN INHIBITOR; RHO KINASE INHIBITOR; ROSTAFUROXIN; SACUBITRIL; SACUBITRIL PLUS VALSARTAN; SOLUBLE EPOXIDE HYDROLASE INHIBITOR; SPARSENTAN; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; CARDIOVASCULAR RISK; DRUG MECHANISM; DRUG TOLERABILITY; HEART DEPOLARIZATION; HEART PROTECTION; HUMAN; HYPERPOLARIZATION; HYPERTENSION; INTRACELLULAR SIGNALING; NONHUMAN; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA RENIN ACTIVITY; PRESSOR RESPONSE; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SMOOTH MUSCLE CONTRACTION; VASOCONSTRICTION; VASODILATATION; ANIMAL; DRUG DEVELOPMENT; PROCEDURES;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DRUG DISCOVERY; HUMANS;

EID: 84928664942     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666141106113018     Document Type: Article

References (290)

1. Lawes, C. M.; Vander Hoorn, S.; Rodgers, A.; International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet, 2008, 371(9623), 1513-1518.
2. Wong, N. D.; Dede, J.; Chow, V. H.; Wong, K. S.; Franklin, S. S. Global cardiovascular risk associated with hypertension and extent of treatment and control according to risk group. Am. J. Hypertens., 2012, 25(5), 561-567.
3. Czernichow. S.; Zanchetti, A.; Turnbull, F.; Barzi, F.; Ninomiya, T.; Kengne, A. P.; Lambers H. J.; Perkovic, V.; Huxley, R.; Arima, H.; Patel, A.; Chalmers, J.; Woodward, M.; MacMahon, S.; Neal, B.; Blood Pressure Lowering Treatment Trialists' Collaboration. The effects of blood pressure reduction and of different blood pressurelowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens., 2011, 29(1), 4-16.
4. Mancia, G.; Fagard, R.; Narkiewicz, K.; Redón, J.; Zanchetti, A.; Böhm, M.; Christiaens, T.; Cifkova, R.; De Backer, G.; Dominiczak, A.; Galderisi, M.; Grobbee, D. E.; Jaarsma, T.; Kirchhof, P.; Kjeldsen, S. E.; Laurent, S.; Manolis, A. J.; Nilsson, P. M.; Ruilope, L. M.; Schmieder, R. E.; Sirnes, P. A.; Sleight, P.; Viigimaa, M.; Waeber, B.; Zannad, F.; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens., 2013, 31(7), 1281-1357.
5. Ruilope, L. M. Long-term adherence to therapy: the clue to prevent hypertension consequences. Eur. Heart. J., 2013, 34(38), 2931-2932.
6. IUPHAR Database of Receptor and Channels. www.guidetopharma cology.org
7. 2+ channels. Physiol. Rev., 2003, 83(1), 117-161.
8. Catterall, W. A. Voltage-gated calcium channels. Cold Spring Harb. Perspect. Biol., 2011, 3(8), a003947.
9. Kuo, I.; Wölfle, S.; Hill, S. T-type calcium channels and vascular function: the new kid on the block? J. Physiol., 2011, 589(Pt. 4), 783-795.
10. 2+ channels in mesenteric and skeletal arteries of SHR. Hypertension, 2002, 40(2), 214-219.
11. 2+ channels: is membrane depolarization the signal? Circ. Res., 2004, 94(10), e97-104.
12. Bean, B. P. Nitrendipine block of cardiac calcium channels: highaffinity binding to the inactivated state. Proc. Natl. Acad. Sci. U. S. A., 1984, 81(20), 6388-6392.
13. 2+ channels. Circ. Res., 1997, 81(4), 526-532.
14. Tzeng, B. H.; Chen, Y. H.; Huang, C. H.; Lin, S. S.; Lee, K. R.; Chen, C. C. The Ca (v) 3.1 T-type calcium channel is required for neointimal formation in response to vascular injury in mice. Cardiovasc. Res., 2012, 96(3), 533-542.
15. 2+ channel subtypes and pharmacology in the kidney. Circ. Res., 2007, 100(3), 342-353
16. 2+ channels. Science, 2003, 302(5649), 416-418.
17. Nikitina, E.; Kawashima, A.; Takahashi, M.; Zhang, Z. D.; Shang, X.; Ai, J.; Macdonald, R. L. Alteration in voltage-dependent calcium channels in dog basilar artery after subarachnoid hemorrhage. Neurosurg., 2010, 113(4), 870-880.
18. Krayenbühl, J. C.; Vozeh, S.; Kondo-Oestreicher, M.; Dayer, P. Drug-drug interactions of new active substances: mibefradil example. Eur. J. Clin. Pharmacol., 1999, 55(8), 559-565.
19. 2+ channel blockers. Bioorg. Med. Chem. Lett., 2004, 14(13), 3379-3384.
20. 2+ channel blockers. Bioorg. Med. Chem. Lett., 2005, 15(2), 283-286.
21. Park, S. J.; Park, S. J.; Lee, M. J.; Rhim, H.; Kim, Y.; Lee, J. H.; Chung, B. Y.; Lee, J. Y. Synthesis and SAR studies of a novel series of T-type calcium channel blockers. Bioorg. Med. Chem., 2006, 14(10), 3502-3511.
22. Kraus, R. L.; Li, Y.; Gregan, Y.; Gotter, A. L.; Uebele, V. N.; Fox, S. V.; Doran, S. M.; Barrow, J. C.; Yang, Z. Q.; Reger, T. S.; Koblan, K. S.; Renger, J. J. In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice. J. Pharmacol. Exp. Ther., 2010, 335(2), 409-417.
23. 2+ channels. Br. J. Pharmacol., 2004, 143(8), 1050-1057.
24. Tanaka, H.; Komikado, C.; Shimada, H.; Takeda, K.; Namekata, I.; Kawanishi, T.; Shigenobu, K. The R (-)-enantiomer of efonidipine blocks T-type but not L-type calcium current in guinea pig ventricular myocardium. J. Pharmacol. Sci., 2004, 96(4), 499-501.
25. Loutzenhiser, R.; Epstein, M. Modification of the renal hemodynamic response to vasoconstrictors by calcium antagonists. Am. J. Nephrol., 1987, 7(suppl 1), 7-16.
26. Hayashi, K.; Homma, K,; Wakino, S.; Tokuyama, H. T-type Ca channel blockade as a determinant of kidney protection. Keijo J. Med., 2010, 59(3), 84-95.
27. 2+ channels (TCCs) as a determinant of Rho-kinase activation and epithelialmesenchymal transition (EMT) in renal injury. J. Hypertens., 2006, 4(suppl 6), 128 Abstract.
28. Wagner, C.; Krämer, K. B.; Hinder, M.; Kieninger, M.; Kurtz, A. Ttype and L-type calcium channel blockers exert opposite effects on renin secretion and renin gene expression in conscious rats. Br, J, Pharmacol., 1998, 124(3), 579-585.
29. +. Am. J. Physiol. Renal. Physiol., 1999, 276(5 Pt 2), F674-F683
30. Nathan, S.; Pepine, J.; Bakris, G. L. Calcium antagonists: effects on cardiorenal risk in hypertensive patients. Hypertension, 2005, 46(4), 637-642.
31. Shudo, C.; Masuda, Y.; Sugita, H.; Tanaka, S.; Tomita, K. Beneficial effect of efonidipine hydrochloride (NZ-105) on proteinuria in aged spontaneously hypertensive rats (SHR). Pharm. Sci., 1995, 1(7), 333-335.
32. Hayashi, K.; Kumagai, H.; Saruta, T. Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment. Am. J. Hypertens., 2003, 16(2), 116-122.
33. Hayashi, K.; Saruta, T.; Goto, Y.; Ishii, M.; JATOS Study Group. Impact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipine. Hypertens. Res., 2010, 33, 1211-1220.
34. Konda, T.; Enomoto, A.; Takahara, A.; Yamamoto, H. Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats. Biol. Pharm. Bull., 2006, 29(5), 933-937.
35. Kario, K.; Nariyama, J.; Kido, H.; Ando, S.; Takiuchi, S.; Eguchi, K.; Niijima, Y.; Ando, T.; Noda, M. Effect of a novel calcium channel blocker on abnormal nocturnal blood pressure in hypertensive patients. J. Clin. Hypertens. (Greenwich), 2013, 15(7), 465-472.
36. Cox, R. H. Changes in the expression and function of arterial potassium channels during hypertension. Vascul. Pharmacol., 2002, 38(1), 13-23.
37. Nelson, M. T. Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am. J. Physiol., 1995, 268(4 Pt 1), C799-C822.
38. Jackson, W. F. Ion Channels and Vascular Tone. Hypertension, 2000, 35(1), 173-178.
39. Amberg, G. C.; Santana, L. F. Downregulation of the BK channel beta1 subunit in genetic hypertension. Circ. Res., 2003, 93(10), 965-971.
40. + channels in genetic and nongenetic hypertension. Circ. Res., 1996, 79(2), 295-301.
41. + channels in the cerebral microcirculation of genetically hypertensive rats: evidence for their protection against cerebral vasospasm. Circ. Res., 1998, 82(6), 729-737.
42. Nelson; M. T.; Cheng, H.; Rubart, M.; Santana, L. F.; Bonev, A. D.; Knot, H. J.; Lederer, W. J. Relaxation of arterial smooth muscle by calcium sparks. Science, 1995, 270(5236), 633-637.
43. Brenner, R.; Peréz, G. J.; Bonev, A. D.; Eckman, D. M.; Kosek, J. C.; Wiler, S. W.; Patterson, A. J.; Nelson, M. T.; Aldrich, R. W. Vasoregulation by the beta1 subunit of the calcium-activated potassium channel. Nature, 2000, 407(6806), 870-876.
44. Yang, Y.; Li, P. Y.; Cheng, J.; Mao, L.; Wen, J.; Tan, X. Q.; Liu, Z. F.; Zeng, X. R. Function of BKCa channels is reduced in human vascular smooth muscle cells from Han Chinese patients with hypertension. Hypertension., 2013, 61(2), 519-525.
45. + channels in vascular smooth muscle during hypertension. J. Clin. Invest, 2003, 112(5), 717-724.
46. Fernández-Fernández, J. M.; Tomás, M.; Vázquez, E.; Orio, P.; Latorre, R.; Senti, M.; Marrugat, J.; Valverde, M. A. Gain-offunction mutation in the KCNMB1 potassium channel subunit is associated with low prevalence of diastolic hypertension. J. Clin. Invest., 2004, 113(7), 1032-1039.
47. Sobey, C. G. Potassium Channel Function in Vascular Disease. Arteriosclerosc. Thromb. Vasc. Biol., 2001, 21, 28-38.
48. + channels. Proc Natl. Acad. Sci. U. S. A., 1996, 93(19), 10489-10494.
49. Quayle, J. M.; Nelson, M. T.; Standen, N. B. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol. Rev., 1997, 77(4), 1165-1232.
50. Tamargo, J.; Caballero, R.; Gómez, R.; Valenzuela, C.; Delpón, E. Pharmacology of cardiac potassium channels. Cardiovasc Res., 2004, 62(1), 9-33.
51. Edwards, F. R.; Hirst, G.d.; Silverberg, G. D. Inward rectification in rat cerebral arterioles; involvement of potassium ions in autoregulation. J. Physiol (Lond)., 1988, 404, 455-466.
52. Edwards, G.; Weston, A. H. Recent advances in potassium channel modulation. Prog. Drug, Res., 1997, 49 (4) 93-121.
53. Pan, Z.; Huang, J.; Cui, W.; Long, C.; Zhang, Y.; Wang, H. Targeting hypertension with a new adenosine triphosphate-sensitive potassium channel opener iptakalim. J. Cardiovasc. Pharmacol., 2010, 56(3), 215-228.
54. Zhao, R. J.; Wang, H. Chemerin/ChemR23 signaling axis is involved in the endothelial protection by KATP channel opener iptakalim. Acta Pharmacol. Sin., 2011, 32(5), 573-580.
55. Wang, H.; Long, C.; Duan, Z.; Shi, C.; Jia, G.; Zhang, Y. A new ATP-sensitive potassium channel opener protects endothelial function in cultured aortic endothelial cells. Cardiovasc. Res., 2007, 73(3), 497-503.
56. Xue, H.; Zhang, Y. L.; Liu, G. S.; Wang, H. A new ATP-sensitive potassium channel opener protects the kidney from hypertensive damage in spontaneously hypertensive rats. J. Pharmacol. Exp. Ther., 2005, 315(2), 501-509.
57. Gao, S.; Long, C. L.; Wang, R. H.; Wang, H. KATP activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function. Cardiovasc. Res., 2009, 83(3), 444-456.
58. Funke-Kaiser, H.; Zollmann, F. S.; Schefe, J. H.; Unger, T. Signal transduction of the (pro) renin receptor as a novel therapeutic target for preventing end-organ damage. Hypertens. Res., 2009, 33(2), 98-104.
59. Nouet, S.; Nahmias, C. Signal transduction from the angiotensin II AT2 receptor. Trends Endocrinol. Metab., 2000, 11(1), 1-6.
60. Funke-Kaiser, H.; Reinemund, J.; Steckelings, U. M.; Unger, T. Adapter proteins and promoter regulation of the angiotensin II type 2 receptor-implications for cardiac pathophysiology. J. Renin. Angiotensin. Aldosterone. Syst., 2010, 11(1), 7-17
61. Paulis, L.; Becker, S. T.; Lucht, K.; Schwengel, K.; Slavic, S.; Kaschina, E.; Thöne-Reineke, C.; Dahlöf, B.; Baulmann, J.; Unger, T.; Steckelings, U. M. Direct angiotensin II type 2 receptor stimulation in Nω-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling. Hypertension, 2012, 59(2), 485-492.
62. Hein, L.; Barsh, G. S.; Pratt, R. E.; Dzau, V. J.; Kobilka, B. K. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature. 1995, 377(6551), 744-747.
63. Falcon, B. L.; Stewart, J. M.; Bourassa, E.; Katovich, M. J.; Walter, G.; Speth, R. C.; Sumners, C.; Raizada, M. K. Angiotensin II type 2 receptor gene transfer elicits cardioprotective effects in an angiotensin II infusion rat model of hypertension. Physiol. Genomics., 2004, 19(3), 255-261.
64. Li, X. C.; Widdop, R. E. AT2 receptor-mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR. Br. J. Pharmacol., 2004, 142(5), 821-830.
65. Siragy, H. M.; Carey, R. M. The subtype 2 (AT2) receptor mediates renal production of nitric oxide in conscious rats. J. Clin. Invest., 1997, 100(2), 264-269.
66. Arima, S.; Endo, Y.; Yaoita, H.; Omata, K.; Ogawa, S.; Tsunoda, K.; Abe, M.; Takeuchi, K.; Abe, K.; Ito, S. Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole. J. Clin. Invest., 1997, 100(11), 2816-2823.
67. 2+)-activated K (+) (BK (Ca)) channels. Hypertension, 2001, 37(2), 301-307.
68. Widdop, R. E.; Jones, E. S.; Hannan, R. E.; Gaspari, T. A. Angiotensin AT2 receptors: cardiovascular hope or hype? Br. J. Pharmacol., 2003, 140(5), 809-824.
69. Guimond, M. O.; Gallo-Payet, N. The Angiotensin II Type 2 Receptor in Brain Functions: An Update. Int. J. Hypertens., 2012, 2012, 351758.
70. Wan, Y.; Wallinder, C.; Plouffe, B.; Beaudry, H.; Mahalingam, A. K.; Wu. X. Johansson B, Holm M, Botoros M, Karlén A, Pettersson A, Nyberg F, Fändriks L, Gallo-Payet N, Hallberg A, Alterman M. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J. Med. Chem., 2004, 47(24), 5995-6008.
71. Bosnyak, S.; Welungoda, I. K.; Hallberg, A.; Alterman, M.; Widdop, R. E.; Jones, E. S. Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br. J. Pharmacol., 2010, 159(3), 709-716.
72. Gelosa, P.; Pignieri, A.; Fändriks, L.; de Gasparo, M.; Hallberg, A.; Banfi, C.; Castiglioni, L.; Turolo, L.; Guerrini, U.; Tremoli, E.; Sironi, L. Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. J. Hypertens., 2009, 27(12), 2444-2451.
73. Rehman A.; Leibowitz, A.; Yamamoto, N.; Rautureau, Y.; Paradis, P.; Schiffrin, E. L. Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension, 2012, 59(2), 291-299.
74. Matavelli, L. C.; Huang, J.; Siragy, H. M. Angiotensin AT receptor stimulation inhibits early renal inflammation in renovascular hypertension. Hypertension., 2011, 57(2), 308-313.
75. Kaschina, E.; Grzesiak, A.; Li, J.; Foryst-Ludwig, A.; Timm, M.; Rompe, F.; Sommerfeld, M.; Kemnitz, U. R.; Curato, C.; Namsolleck, P.; Tschöpe, C.; Hallberg, A.; Alterman, M.; Hucko, T.; Paetsch, I.; Dietrich, T.; Schnackenburg, B.; Graf, K.; Dahlöf, B.; Kintscher, U.; Unger, T.; Steckelings, U.. ngiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation, 2008, 118(24), 2523-2532.
76. Rompe, F.; Artuc, M.; Hallberg, A.; Alterman, M.; Ströder, K.; Thöne-Reineke, C.; Reichenbach, A.; Schacherl, J.; Dahlöf, B.; Bader, M.; Alenina, N.; Schwaninger, M.; Zuberbier, T.; Funke-Kaiser, H.; Schmidt, C.; Schunck, WH.; Unger, T.; Steckelings, U. M. Direct angiotensin II type 2 receptor stimulation acts antiinflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor {kappa}B. Hypertension, 2010, 55(4), 924-931.
77. De Wire, S. M.; Violin, J. D. Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology. Circ. Res., 2011, 109(2), 205-216.
78. Violin, J. D.; Dewire, S. M.; Yamashita, D.; Rominger, D. H.; Nguyen, L.; Schiller, K.; Whalen, E. J.; Gowen, M.; Lark, M. W. Selectively engaging β-arrestins at the AT1R reduces blood pressure and increases cardiac performance. J. Pharmacol. Exp. Ther., 2010, 335(3), 572-579.
79. Boerrigter, G.; Soergel, D. G.; Violin, J. D.; Lark, M. W.; Burnett, J. C. Jr. TRV120027, a novel β-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. Circ. Heart. Fail., 2012, 5(5), 627-634.
80. Jensen, C.; Herold, P.; Brunner, H. R. Aliskiren: the first renin inhibitor for clinical treatment. Nat. Rev. Drug Discov., 2008, 7(5), 399-410.
81. Burcklé, CA.; Jan Danser, A. H.; Müller, D. N.; Garrelds, I. M.; Gasc J. M.; Popova, E.; Plehm, R.; Peters, J.; Bader, M.; Nguyen, G. Elevated blood pressure and heart rate in human renin receptor transgenic rats. Hypertension, 2006, 47(3), 552-556.
82. Nguyen, G.; Muller, D. N. The Biology of the (Pro) Renin Receptor. J. Am. Soc. Nephrol., 2010, 21(1), 18-23.
83. Huang, Y.; Wongamorntham, S.; Kasting, J.; McQuillan, D.; Owens, R. T.; Yu, L.; Noble, N. A.; Border, W. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int., 2006, 69(1), 105-113.
84. Schefe, J. H.; Unger, T.; Funke-Kaiser, H. PLZF and the (pro) renin receptor. J. Mol. Med., 2008, 86(6), 623-627.
85. Duggan, S. T. Chwieduk CM, Curran MP. Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension. Drugs, 2010, 70(15), 2011-2049.
86. Paulis, L.;, Unger, T. Novel therapeutic targets for hypertension. Nat. Rev. Cardiol., 2010, 7(8), 431-441.
87. Sealey, J. E.; Laragh, J. H. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am. J. Hypertens., 2007, 20(5), 587-597.
88. Gradman, A. H.; Kad, R. Renin inhibition in hypertension. J. Am. Coll. Cardiol., 2008, 51(5), 519-528.
89. Ménard. J.; Azizi, M. The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren. J. Hypertens., 2007, 25(9), 1775-1782.
90. Schefe, J. H.; Neumann, C.; Goebel, M.; Danser, J.; Kirsch, S.; Gust, R.; Kintscher, U.; Unger, T.; Funke-Kaiser, H. Prorenin engages the (pro) renin receptor like renin and both ligand activities are unopposed by aliskiren. J. Hypertens., 2008, 26(9), 1787-1794.
91. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Suzuki F, Nakagawa T, et al. Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension, 2006, 47(5), 894-900.
92. Ruilope, L. M. Renin-angiotensin system blockade: time for a reappraisal? Eur. Heart J., 2014, 35(26), 1703-1705.
93. Jia, L.; Simpson, R. D.; Yuan, J.; Xu, Z.; Zhao, W.; Cacatian, S.; Tice, C. M.; Guo, J.; Ishchenko, A.; Singh, S. B.; Wu, Z.; McKeever, B. M.; Bukhtiyarov, Y.; Johnson, J. A.; Doe, C. P.; Harrison, R. K.; McGeehan, G. M.; Dillard, L. W.; Baldwin, J. J.; Claremon, D. A. Discovery of VTP-27999, an alkyl amine renin inhibitor with potential for clinical utility. ACS Med. Chem. Lett., 2011, 2(10), 747-751.
94. Krop, M.; Lu, X.; Verdonk, K.; Schalekamp, M. A.; van Gool, J. M.; McKeever, B. M.; Gregg, R.; Danser, A. H. New renin inhibitor VTP-27999 alters renin immunoreactivity and does not unfold prorenin. Hypertension, 2013, 61(5), 1075-1082.
95. Marc, Y.; Gao, J.; Balavoine, F.; Michaud, A.; Roques, B. P.; Llorens-Cortes, C. Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats. Hypertension, 2012, 60(2), 411-418.
96. Phillips, M. I. Functions of angiotensin in the central nervous system. Annu. Rev. Physiol., 1987, 49, 413-435.
97. Fournie-Zaluski, M. C.; Fassot, C.; Valentin, B.; Djordjijevic, D.; Reaux-Le Goazigo, A.; Corvol, P.; Roques, B. P.; Llorens-Cortes, C. Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of saltdependent hypertension. Proc. Natl. Acad. Sci. U. S. A., 2004, 101(20), 7775-7780.
98. Bodineau, L.; Frugière, A.; Marc, Y.; Inguimbert, N.; Fassot, C.; Balavoine, F.; Roques, B.; Llorens-Cortes, C. Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension. Hypertension, 2008, 51(5), 1318-1325.
99. Donoghue, M.; Hsieh, F.; Baronas, E.; Godbout, K.; Gosselin, M.; Stagliano, N.; Donovan, M.; Woolf, B.; Robison, K.; Jeyaseelan, R.; Breitbart, R. E.; Acton, S. A novel angiotensin-converting enzymerelated carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circulation Research, 2000, 87(5), E1-E9.
100. Fleming, I.; Kohlstedt, K.; Busse, R. New fACEs to the Renin-Angiotensin System. Physiology, 2005, 20, 91-95.
101. Tipnis, S. R.; Hooper, N. M.; Hyde, R.; Karran, E.; Christie, G.; Turner, A. J.. A human homolog of angiotensin converting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem., 2000, 275(43), 33238-33243.
102. Soler, M.; Barrios, C.; Oliva, R.; Battle, D. Pharmacological modulation of ACE2 expression. Curr. Hypert. Reports, 2008, 10, 410-414.
103. Díez-Freire, C.; Vázquez, J.; Correa de Adjounian, M. F.; Ferrari, M. F.; Yuan, L.; Silver, X.; Torres, R.; Raizada, M. K. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol. Genomics., 2006, 27(1), 12-19.
104. Santos, R. A.; Simoes e Silva, A. C.; Maric, C.; Silva, D. M.; Machado, R, P.; de Buhr, I.; Heringer-Walther, S.; Pinheiro, S. V.; Lopes MT, Bader, M.; Mendes, E. P.; Lemos, V. S.; Campagnole-Santos, M. J.; Schultheiss, H. P.; Speth, R.; Walther, T. Angiotensin-(1-7) is an endogenous ligand for the Gprotein-coupled receptor Mas. Proc. Natl. Acad. Sci. U S A., 2003, 100(14), 8258-8263.
105. Santos, R. A.; Ferreira, A. J.; Verano-Braga, T.; Bader, M. Angiotensinconverting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J. Endocrinol., 2013, 216(2), R1-R17.
106. Gava, E.; de Castro C. H.; Ferreira, A. J.; Colleta, H.; Melo, M. B.; Alenina, N.; Bader, M.; Oliveira, L. A.; Santos, R. A.; Kitten, G. T. Angiotensin-(1-7) receptor Mas is an essential modulator of extracellular matrix protein expression in the heart. Regul. Pept., 2012, 175(1-3), 30-42.
107. Sampaio, W. O.; Henrique de Castro, C.; Santos, R. A.; Schiffrin, E. L.; Touyz, R. M. Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension, 2007, 50(6), 1093-1098.
108. Sampaio WO, Souza dos Santos RA, Faria-Silva R, da Mata Machado LT, Schiffrin L, Touyz RM. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension, 2007, 49(1), 185-192.
109. Ferreira, A. J.; Santos, R. A.; Bradford, C. N.; Mecca, A. P.; Sumners, C.; Katovich, M. J.; Raizada, M. K. Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension, 2010, 55(2), 207-213.
110. Su, Z.; Zimpelmann, J.; Burns, K. D.; Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int., 2006, 69(12), 2212-2218.
111. Pearson, G.; Robinson, F.; Beers Gibson, T.; Xu. B. E.; Karandikar, M.; Berman, K.; Cobb, M. H. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev., 2001, 22(2), 153-183.
112. Grobe, J. L.; Mecca, A. P.; Lingis, M.; Shenoy, V.; Bolton, T. A.; Machado, J. M.; Speth, R. C.; Raizada, M. K.; Katovich, M. J. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). American Journal of Physiology. Heart and Circulatory Physiology, 2007, 292(2), H736-H742.
113. Grobe, J. L.; Mecca, A. P.; Mao, H.; Katovich, M. J. Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. American Journal of Physiology. Heart and Circulatory Physiology, 2006, 290(6), H2417-H2423.
114. Hernández Prada, J. A.; Ferreira, A. J.; Katovich, M. J.; Shenoy, V.; Qi, Y.; Santos, R. A.; Castellano, R. K.; Lampkins, A. J.; Gubala, V.; Ostrov, D. A.; Raizada, M. K. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension, 2008, 51(5), 1312-1317.
115. Murça, T. M.; Almeida, T. C.; Raizada, M. K.; Ferreira, A. J. Chronic activation of endogenous angiotensin-converting enzyme 2 protects diabetic rats from cardiovascular autonomic dysfunction. Exp. Physiol., 2012, 97(6), 699-709.
116. Murça, T. M.; Moraes, P. L.; Capuruço, C. A.; Santos, S. H.; Melo, M. B.; Santos, R. A.; Shenoy, V.; Katovich, M. J.; Raizada, M. K.; Ferreira, A. J. Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction. Regul. Pept. 2012, 177(1-3), 107-115.
117. Prada,. J. A.;, Ferreira, A. J.; Katovich, M. J.; Shenoy, V.; Qi, Y.; Santos, R. A.; Castellano, R. K.; Lampkins, A. J.; Gubala, V.; Ostrov, D. A.; Raizada, M. K. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension, 2008, 51(5), 1312-1317.
118. Wysocki, J.; Ye, M.; Rodriguez, E.; González-Pacheco, F. R.; Barrios, C.; Evora, K.; Schuster, M.; Loibner, H.; Brosnihan, K. B.; Ferrario, C. M.; Penninger, J. M.; Batlle, D. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension, 2010, 55(1), 90-98.
119. Pinheiro, S. V.; Simoes e Silva, A. C.; Sampaio, W. O.; de Paula, R. D.; Mendes, E. P.; Bontempo, E. D.; Pesquero, J. B.; Walther, T.; Alenina, N.; Bader, M.; Bleich, M.; Santos, R. A. 2004 Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension, 2004, 44(4), 490-496.
120. Lemos, V. S.; Silva, D. M.; Walther, T.; Alenina, N.; Bader, M.; Santos, R. A. The endothelium-dependent vasodilator effect of the nonpeptide Ang (1-7) mimic AVE 0991 is abolished in the aorta of mas-knockout mice. Journal of Cardiovascular Pharmacology, 2005, 46(3), 274-279.
121. Ferreira, A. J.; Jacoby, B. A.; Araujo, C. A.; Macedo, F. A.; Silva, G. A.; Almeida, A. P.; Caliari, V.; Santos, R. A. The nonpeptide angiotensin-(1-7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction. American Journal of Physiology Heart and Circulatory Physiology, 2007, 292(2), H1113-H1119.
122. Ferreira, A. J.; Oliveira, T. L.; Castro, M. C.; Almeida, A. P.; Castro, C. H.; Caliari, M. V.; Gava, E.; Kitten, G. T.; Santos, R. A. Isoproterenolinduced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin-(1-7) analogue AVE 0991. Life Sciences, 2007, 81(11), 916-923.
123. Benter, I. F.; Yousif, M. H.; Anim, J. T.; Cojocel, C.; Diz, D. I. Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. American Journal of Physiology. Heart and Circulatory Physiology, 2006, 290(2), H684-H691.
124. Savergnini, S. Q.; Beiman, M.; Lautner, R. Q.; de Paula-Carvalho, V.; Allahdadi, K.; Pessoa, D. C.; Costa-Fraga, F. P.; Fraga-Silva, R. A.; Cojocaru, G.; Cohen, Y.; Bader, M.; de Almeida, A. P.; Rotman, G.; Santos, R. A. Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. Hypertension, 2010, 56(1), 112-120.
125. Marques, F. D.; Melo, M. B.; Souza, L. E.; Irigoyen, M. C.; Sinisterra, R. D.; de Sousa, F. B.; Savergnini, S. Q.; Braga, V. B.; Ferreira, A. J.; Santos, R. A. Beneficial effects of long-term administration of an oral formulation of angiotensin-(1-7) in infarcted rats. International Journal of Hypertension, 2012, 2012, 795452.
126. Downham, M. R.; Auton, T. R.; Rosul, A.; Sharp, H. L.; Sjöström, L.; Rushton, A.; Richards, J. P.; Mant, T. G.; Gardiner, S. M.; Bennett, T.; Glover, J. F. Evaluation of two carrier proteinangiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man. Br. J. Clin. Pharmacol., 2003, 56(5), 505-512.
127. Brown, M. J.; Coltart, J.; Gunewardena, K.; Ritter, J. M.; Auton, T. R.; Glover, J. F. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin. Sci. (Lond.), 2004, 107(2), 167-173.
128. Ambühl, P. M.; Tissot, A. C.; Fulurija, A.; Maurer, P.; Nussberger, J.; Sabat. R.; Nief, V.; Schellekens, C.; Sladko, K.; Roubicek, K.; Pfister, T.; Rettenbacher, M.; Volk, H. D.; Wagner, F.; Müller, P.; Jennings, G. T.; Bachmann, M. F. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J. Hypertens., 2007, 25(1), 63-72.
129. Tissot, A. C.; Maurer, P.; Nussberger, J.; Sabat, R.; Pfister, T.; Ignatenko, S.; Volk, H. D.; Stocker, H.; Müller, P.; Jennings, G. T.; Wagner, F.; Bachmann, M. F. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet, 2008, 371(9615), 821-827.
130. Chen, X.; Qiu, Z.; Yang, D.; Ding, D.; Chen, F.; Zhou, Y.; Wang, M.; Lin, J.; Yu, X.; Zhou, Z.; Liao, Y. Effectiveness and safety of a therapeutic vaccine against angiotensin ii receptor type 1 in hypertensive animals. Hypertension, 2013, 61(2), 408-416.
131. Xanthakis, V.; Vasan, R. S. Aldosterone and the risk of hypertension. Curr. Hypertens. Rep., 2013, 15(2), 102-107.
132. Marney, A. M.; Brown, N. J. Aldosterone and end-organ damage. Clin. Sci. (Lond.), 2007, 113 (6) 267-278.
133. Zannad, F.; Gattis Stough, W.; Rossignol, P.; Bauersachs, J.; McMurray, J. J.; Swedberg, K.; Struthers, A. D.; Voors, A. A.; Ruilope, L. M.; Bakris, G. L.; O'Connor, C. M.; Gheorghiade, M.; Mentz, R. J.; Cohen-Solal, A.; Maggioni, A. P.; Beygui, F.; Filippatos, G. S.; Massy, Z. A.; Pathak, A.; Piña, I. L.; Sabbah, H. N.; Sica, D. A.; Tavazzi, L.; Pitt, B. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur. Heart. J., 2012, 33(22), 2782-2795.
134. Calhoun, D. A. Hyperaldosteronism as a common cause of resistant hypertension. Annu. Rev. Med., 2013, 64, 233-247.
135. Grandi, A. M.; Imperiale, D.; Santillo, R.; Barlocco, E.; Bertolini, A.; Guasti, L.; Venco, A. Aldosterone antagonist improves diasto lic function in essential hypertension. Hypertension, 2002, 40(5), 647-652.
136. Shah, N. C.; Pringle, S. D.; Donnan, P. T.; Struthers, A. D. Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. J. Hypertens., 2007, 25(11), 2345-2351.
137. Tamargo, J.; Solini, A.; Ruilope LM. Comparison of agents that affect aldosterone action. Semin Nephrol., 2014, 34(3), 285-306.
138. Piotrowski, D. W. Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy. J. Med. Chem., 2012, 55(18), 7957-7966.
139. Funder, J. W. Aldosterone and mineralocorticoid receptors: a personal reflection. Mol. Cell. Endocrinol., 2012, 350(2), 146-50.
140. Fagart, J.; Hillisch, A.; Huyet, J.; Bärfacker, L.; Fay, M.; Pleiss, U.; Pook, E.; Schäfer, S.; Rafestin-Oblin, M. E.; Kolkhof, P. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J. Biol. Chem., 2010, 285(39), 29932-29940.
141. Meyers, M. J.; Arhancet, G. B.; Hockerman, S. L.; Chen, X.; Long, S. A.; Mahoney, M. W.; Rico, J. R.; Garland, D. J.; Blinn, J. R.; Collins, J. T.; Yang, S.; Huang, H. C.; McGee, K. F.; Wendling, J. M.; Dietz, J. D.; Payne, M. A.; Homer, B. L.; Heron, M. I.; Reitz, D. B.; Hu, X. Discovery of (3S, 3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3, 3a, 4, 5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. J Med Chem., 2010, 53(16), 5979-6002.
142. Dietz, J. D.; Du, S.; Bolten, C. W.; Payne, M. A.; Xia, C.; Blinn, J. R.; Funder, J. W.; Hu, X. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension, 2008, 51(3), 742-748.
143. Arhancet, G. B.; Woodard, S. S.; Dietz, J. D.; Garland, D. J.; Wagner, G. M.; Iyanar, K.; Collins, J. T.; Blinn, J. R.; Numann, R. E.; Hu, X.; Huang, H. C. Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines. J. Med. Chem., 2010, 53(10), 4300-4304.
144. Bärfacker, L.; Kuhl, A.; Hillisch, A.; Grosser, R.; Figueroa-Perez, S.; Heckroth, H.; Nitsche, A.; Erguden, J. K.; Gielen-Haertwig, H.; Schlemmer, K. H.; Mittendorf, J.; Paulsen, H.; Platzek, J.; Kolkhof, P. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem, 2012, 7(8), 1385-1403.
145. Kolkhof, P.; Kretschmer, A.; Baerfacker, L.; Hartmann, E.; Schaefer, S. Improved survival and nephroprotection in hypertensive rats by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist. Eur. Heart J., 2012, 33(Abstract Suppl), 978.
146. Delbeck M, Kretschmer A, Kast R, Bärfacker L, Hartmann E, Schaefer S, Kolkhof P. Cardiorenal protection by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist in a preclinical model of hypertension and diastolic heart failure. Eur Heart J 2012;33(Abstract Suppl), 772.
147. Albrecht-Kuepper, B.; Kretschmer, A.; Kast, R.; Baerfacker, L.; Schaefer, S.; Kolkhof, P.; Pronounced cardiac protection by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist in a preclinical rat model of heart failure. Eu.r Heart. J., 2012;32(Abstract Suppl), 7.
148. Pitt, B.; Kober, L.; Ponikowski, P.; Gheorghiade, M.; Filippatos, G.; Krum, H.; Nowack, C.; Kolkhof, P.; Kim, S. Y.; Zannad, F. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur. Heart J., 2013, 34(31), 2453-2463.
149. Azizi, M.; Amar, L.; Menard, J. Aldosterone synthase inhibition in humans. Nephrol. Dial. Transplant., 2013, 28(1), 36-43.
150. Fiebeler, A.; Nussberger, J.; Shagdarsuren, E.; Rong, S.; Hilfenhaus, G.; Al-Saadi, N.; Dechend, R.; Wellner, M.; Meiners, S.; Maser-Gluth, C.; Jeng, A. Y.; Webb, R. L.; Luft, F. C.; Muller, D. N. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation, 2005, 111(23), 3087-3094.
151. Fleming I, Kohlstedt K, Busse R. New fACEs to the Renin-Angiotensin System. Physiology 2005;20, 91-95.
152. Mulder, P.; Mellin, V.; Favre, J.; Vercauteren, M.; Remy-Jouet, I.; Monteil, C.; Richard, V.; Renet, S.; Henry, J. P.; Jeng, A. Y. Webb RL, Thuillez C. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur. Heart. J., 2008, 29(17), 2171-2179.
153. Menard, J.; Watson, C.; Rebello, S.; Zhang, Y. M.; Dole, W. P. Hormonal and electrolyte responses to the aldosterone synthase inhibitor lci699 in sodium depleted healthy subjects. J. Am. Coll. Cardiol., 2010, 55(10), A61.
154. Amar, L.; Azizi, M.; Menard, J.; Peyrard, S.; Watson, C.; Plouin, P. F. Aldosterone synthase inhibition with LCI699: a proof-ofconcept study in patients with primary aldosteronism. Hypertension, 2010, 56(5), 831-838.
155. Calhoun, D. A.; White, W. B.; Krum, H.; Guo, W.; Bermann, G.; Trapani, A.; Lefkowitz, M. P.; Ménard, J. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation, 2011, 124(18), 1945-1955.
156. Isaka, T.; Ikeda, K.; Takada, Y.; Inada, Y.; Tojo, K.; Tajima, N. Azelnidipine inhibits aldosterone synthesis and secretion in human adrenocortical cell line NCI-H295R. Eur. J. Pharmacol., 2009, 605(1-3), 49-52.
157. 2+ channel antagonists. Int. J. Endocrinol., 2012, 2012, 519467.
158. 2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur. J. Pharmacol., 2008, 584(2-3), 424-434.
159. Rich, S.; McLaughlin, V. V. Endothelin receptor blockers in cardiovascular disease. Circulation., 2003, 108(18), 2184-2190.
160. Tamargo, J.; Amorós, I,; Barana, A.; Caballero, R.; Delpón, E. New investigational drugs for the management of acute heart failure syndromes. Curr. Med. Chem., 2010, 17(4), 363-390.
161. Sica, D. A. Endothelin receptor antagonism: what does the future hold? Hypertension, 2008, 52(3), 460-461.
162. Lazich, I.; Bakris GL. Endothelin antagonism in patients with resistant hypertension and hypertension nephropathy. Contrib Nephrol., 2011, 172, 223-34.
163. Weber, M. A.; Black, H.; Bakris, G.; Krum, H.; Linas, S.; Weiss, R.; Linseman, J. V.; Wiens, B. L.; Warren, M. S.; Lindholm, L. H. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, doubleblind, placebo-controlled trial. Lancet, 2009, 374(9699), 1423-1431.
164. Bakris, G. L.; Lindholm, L. H.; Black, H. R.; Krum, H.; Linas, S.; Linseman, J. V.; Arterburn, S.; Sager, P.; Weber, M. Divergent results using clinic and ambulatory blood pressures: report of a darusentanresistant hypertension trial. Hypertension, 2010, 56, 824-830.
165. Murugesan, N.; Tellew, JE.; Gu, Z.; Kunst, BL.; Fadnis, L.; Cornelius, L. A.; Baska, R. A.; Yang, Y.; Beyer, S. M.; Monshizadegan, H.; Dickinson, K. E.; Panchal, B.; Valentine, M. T.; Chong, S.; Morrison, R. A.; Carlson, K. E.; Powell, J. R.; Moreland, S.; Barrish, J. C.; Kowala, M. C.; Macor, J. E. Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists. J. Med. Chem., 2002, 45(18), 3829-3835.
166. Murugesan, N.; Gu, Z.; Fadnis, L.; Tellew, J. E.; Baska, R. A.; Yang, Y.; Beyer, S. M.; Monshizadegan, H.; Dickinson, K. E.; Valentine, M. T.; Humphreys, W. G.; Lan, S. J.; Ewing, W. R.; Carlson, K. E.; Kowala, M. C.; Zahler, R.; Macor, J. E. Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics. J. Med. Chem., 2005, 48(1), 171-179.
167. Neutel, J. M.; Germino, W. F.; Punzi, H.; McBride, M.; Bryson, C. C.; Belder R. Results of a double blind placebo controlled study to evaluate the efficacy and safety of PS433540 in human subjects with hypertension. Circulation., 2008;118, S886.
168. Corti, R.; Burnett, J. C. Jr.; Rouleau, J. L.; Ruschitzka, F.; Luscher, T. F. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation, 2001, 104(15), 1856-1862.
169. Campbell, D. J. Vasopeptidase inhibition: a double-edged sword? Hypertension, 2003, 41(3), 383-388.
170. Davidson, E. P.; Coppey, L. J.; Holmes, A.; Dake, B.; Yorek, M. A. Effect of treatment of high fat fed/low dose streptozotocin-diabetic rats with Ilepatril on vascular and neural complications. Eur. J. Pharmacol., 2011, 668(3), 497-506.
171. Weckler, N.; Leitzbach, D.; Kalinowski. L.; Malinski, T.; Busch, A. E.; Linz, W. Effect of chronic treatment with the vasopeptidase inhibitor AVE 7688 and ramipril on endothelial function in atherogenic diet rabbits. J. Renin Angiotensin Aldosterone Syst., 2003, 4(3), 191-196.
172. Azizi, M.; Bissery, A.; Peyrard, S.; Guyene, T. T.; Ozoux, M. L.; Floch, A.; Ménard, J. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans. Clin. Pharmacol. Ther., 2006, 79(1), 49-61.
173. Tabrizchi, R. SLV-306. Solvay. Curr Opin Investig Drugs., 2003, 4(3), 329-332.
174. Thöne-Reinke, C.; Simon, K.; Richter, C. M.; Godes, M.; Neumayer, H. H.; Thormählen, D.; Hocher, B. Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats. J. Cardiovasc. Pharmacol., 2004, 44(Suppl 1), S76-S79.
175. Seed, A.; Kuc, R. E.; Maguire, J. J.; Hillier, C.; Johnston, F.; Essers, H.; de Voogd, H. J.; McMurray, J.; Davenport, A. P. The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci., 2012, 91(13-14), 743-748.
176. Dickstein, K.; De Voogd, H. J.; Miric, M. P.; Willenbrock, R.; Mitrovic, V.; Pacher, R.; Koopman, P. A. Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelinconverting enzyme, on pulmonary pressures in congestive heart failure. Am. J. Cardiol., 2004, 94(2), 237-239.
177. Parvanova, A.; van der Meer, I. M.; Iliev, I.; Perna, A.; Gaspari, F.; Trevisan, R.; Bossi, A.; Remuzzi, G.; Benigni, A.; Ruggenenti, P.; for the Daglutril in Diabetic Nephropathy Study Group. Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, doubleblind, placebo-controlled trial. The Lancet Diabetes & Endocrinol., 2013, 1(1), 19-27.
178. Kalk, P.; Sharkovska, Y.; Kashina, E.; von Websky, K.; Relle, K.; Pfab, T.; Alter, M.; Guillaume, P.; Provost, D.; Hoffmann, K.; Fischer, Y.; Hocher, B. Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner. Hypertension, 2011, 57(4), 755-763.
179. Sharkovska, Y.; Kalk, P.; von Websky, K.; Relle, K.; Pfab, T.; Alter, M.; Fischer, Y.; Hocher, B. Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage. Clin. Lab., 2011, 57(7-8), 507-515.
180. Wengenmayer, C.; Krikov, M.; Mueller, S.; Lucht, K.; Villringer, A.; Hocher, B.; Unger, T.; Thoene-Reineke, C. Novel therapy approach in primary stroke prevention: simultaneous inhibition of endothelin converting enzyme and neutral endopeptidase in spontaneously hypertensive, stroke-prone rats improves survival. Neurol. Res., 2011, 33(2), 201-207.
181. Gu, J.; Noe, A.; Chandra, P.; Al-Fayoumi, S.; Ligueros-Saylan, M.; Sarangapani, R.; Maahs, S.; Ksander, G.; Rigel, D. F.; Jeng, A. Y.; Lin, T. H.; Zheng, W.; Dole, W. P. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J. Clin. Pharmacol., 2010, 50(4), 401-414.
182. Ruilope, L. M.; Dukat, A.; Böhm, M.; Lacourcière, Y.; Gong, J.; Lefkowitz, M. P. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet, 2010, 375(9722), 1255-1266.
183. Solomon, S. D.; Zile, M.; Pieske, B.; Voors, A.; Shah, A.; Kraigher-Krainer, E.; Shi, V.; Bransford, T.; Takeuchi, M.; Gong, J.; Lefkowitz, M.; Packer, M.; McMurray, J. J.; Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet, 2012, 380(9851), 1387-1395.
184. McMurray, J. J.; Packer, M.; Desai, A. S.; Gong, J.; Lefkowitz, M. P.; Rizkala, A. R.; Rouleau, J. L.; Shi. V. C.; Solomon, S. D.; Swedberg, K.; Zile, M. R.; the PARADIGM-HF Investigators and Committees. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. N. Engl. J. Med., 2014. [Epub ahead of print]
185. Susic, D. Cross-link breakers as a new therapeutic approach to cardiovascular disease. Biochem. Soc. Trans., 2007, 35(Pt 5), 853-856.
186. Thomas, M. C.; Baynes, J. W.; Thorpe, S. R.; Cooper, M. E. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr. Drug Targets, 2005, 6(4), 453-474.
187. Zieman, S. J.; Melenovsky, V.; Clattenburg, L.; Corretti, M. C.; Capriotti, A.; Gerstenblith, G.; Kass, D. A. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J. Hypertens., 2007, 25(3), 577-583.
188. Petrova, R.; Yamamoto, Y.; Muraki, K.; Yonekura, H.; Sakurai, S.; Watanabe, T.; Li, H.; Takeuchi, M.; Makita, Z.; Kato, I.; Takasawa, S.; Okamoto, H.; Imaizumi, Y.; Yamamoto, H. Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J. Mol. Cell. Cardiol., 2002, 34(10), 1425-1431.
189. Vasan, S.; Foiles, P.; Founds, H. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch. Bioche. Biophys., 2003, 419(1), 89-96.
190. Chandra, K. P.; Shiwalkar, A.; Kotecha, J.; Thakkar, P.; Srivastava, A.; Chauthaiwale, V.; Sharma, S. K.; Cross, M. R.; Dutt, C. Phase I clinical studies of the advanced glycation end-product (AGE) - breaker TRC4186: safety, tolerability and pharmacokinetics in healthy subjects. Clin. Drug. Investig., 2009, 29(9), 559-575.
191. Bakris, G. L.; Bank, A. J.; Kass, D. A.; Neutel, J. M.; Preston, R. A.; Oparilm, S. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am. J. Hypertens., 2004, 17(12 Pt 2), 23S-30S.
192. Joshi, D.; Gupta, R.; Dubey, A.; Shiwalkar, A.; Pathak, P.; Gupta, R. C.; Chauthaiwale, V.; Dutt, C. TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in Ob-ZSF1 model of type 2 diabetes. J. Cardiovasc. Pharmacol., 2009, 54(1), 72-81.
193. Hartog, J. W.; Willemsen, S.; van Veldhuisen, D. J; Posma, J. L.; van Wijk, L. M.; Hummel, Y. M.; Hillege, H. L.; Voors, A. A.; BENEFICIAL investigators. Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur. J. Heart Fail., 2011, 13(8), 899-908.
194. Ferrandi, M.; Molinari, I.; Barassi, P.; Minotti, E.; Bianchi, G.; Ferrari, P. Organ hypertrophic signaling within caveolae membrane subdomains triggered by ouabain and antagonized by PST2238, J. Biol. Chem., 2004, 279(32), 33306-33314.
195. +-ATPase alterations in ouabain and adducin-dependent hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2006, 290(3), R529-R535.
196. Ferrari, P. Rostafuroxin: an ouabain-inhibitor counteracting specific forms of hypertension. Biochim. Biophys. Acta., 2010, 1802(12), 1254-1258.
197. Bagrov, A. Y.; Shapiro, J. I.; Fedorova, O. V. Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. Pharmacol. Rev., 2009, 61(1), 9-38.
198. Bianchi, G.; Ferrari, P.; Staessen, J. A. Adducin polymorphism: detection and impact on hypertension and related disorders. Hypertension. 2005, 45(3), 331-340.
199. Staessen, J. A.; Thijs, L.; Stolarz-Skrzypek, K.; Bacchieri, A.; Barton, J.; Espositi, E. D.; de Leeuw, P. W.; Dłuzniewski, M.; Glorioso, N.; Januszewicz, A.; Manunta, P.; Milyagin, V.; Nikitin, Y.; Souç-ek, M.; Lanzani, C.; Citterio, L.; Timio, M.; Tykarski, A.; Ferrari, P.; Valentini, G.; Kawecka-Jaszcz, K.; Bianchi, G. Main results of the ouabain and adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin. Trials, 2011, 14(1), 12-13.
200. Dell'Italia, L. J.; Husain, A. Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases. Curr. Opin. Cardiol., 2002, 17(4), 374-379.
201. Guo, C.; Ju, H.; Leung, D.; Massaeli, H.; Shi, M.; Rabinovitch, M. A novel vascular smooth muscle chymase is upregulated in hypertensive rats. J. Clin. Invest., 2001, 107(6), 703-715
202. Takai, S.; Jin, D.; Miyazaki, M. Multiple mechanisms for the action of chymase inhibitors. J. Pharmacol. Sci., 2012, 118(3), 311-316.
203. Tojo, H.; Urata, H. Chymase inhibition and cardiovascular protection. Cardiovasc. Drugs. Ther., 2013, 27(2), 139-43.
204. Taipale, J.; Lohi, J.; Saarinen, J.; Kovanen, P. T.; Keski-Oja, J. Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular matrix of cultured human epithelial and endothelial cells. J. Biol. Chem., 199, 270(9), 4689-4696.
205. Jin, D.; Takai, S.; Yamada, M.; Sakaguchi, M.; Kamoshita, K.; Ishida, K.; Sukenaga, Y.; Miyazaki, M. Impact of chymase inhibitor on cardiac function and survival after myocardial infarction. Cardiovasc. Res., 2003, 60(2), 413-420.
206. Wang, R. Physiological implications of hydrogen sulfide: A whiff exploration that blossomed. Physiol. Rev., 2012, 92(2), 791-896.
207. Liu, Y. H.; Lu, M.; Hu, L. F.; Wong, P. T.; Webb, G. D.; Bian, J. S. Hydrogen sulfide in the mammalian cardiovascular system. Antioxid. Redox Signal, 2012, 17(1), 141-185.
208. David J. Polhemus, D. J.; Lefer, D. J. Emergence of hydrogen sulfide as an endogenous gaseous signaling molecule in cardiovascular disease. Circ. Res., 2014, 114(3), 730-737
209. Köhn, C.; Dubrovska, G.; Huang, Y.; Gollasch, M. Hydrogen sulfide: potent regulator of vascular tone and stimulator of angiogenesis. Int J Biomed Sci., 2012, 8(2), 81-86.
210. Nicholson, C. K.; Calvert, J. W. Hydrogen sulfide and ischemiareperfusion injury. Pharmacol. Res., 2010, 62(4), 289-297.
211. Lim, J. J.; Liu, Y. H.; Khin, E. S.; Bian, J. S. Vasoconstrictive effect of hydrogen sulfide involves downregulation of cAMP in vascular smooth muscle cells. Am. J. Physiol. Cell Physiol., 2008, 295(5), C1261-1270.
212. Mustafa, A. K.; Sikka, G.; Gazi, S. K.; Steppan, J.; Jung, S. M.; Bhunia, A. K.; Barodka, V. M.; Gazi, F. K.; Barrow, R. K.; Wang, R.; Amzel, L. M.; Berkowitz, D. E.; Snyder, S. H. Hydrogen sulfide as endothelium-derived hyperpolarizing factor sulfhydrates potassium channels, Circulation Research, 2011, 109(11), 1259-1268.
213. Schleifenbaum, J.; Köhn, C.; Voblova, N.; Dubrovska, G.; Zavarirskaya, O.; Gloe, T.; Crean, C. S.; Luft, F. C.; Huang, Y.; Schubert, R.; Gollasch, M. Systemic peripheral artery relaxation by kcnq channel openers and hydrogen sulfide. J. Hypertens., 2010, 28(9), 1875-1882.
214. Jiang, B.; Tang, G.; Cao, K.; Wu, L.; Wang, R. Molecular mechanism for H (2) Sinduced activation of KATP channels. Antioxid. Redox. Signal, 2010, 12(10), 1167-1178.
215. Munaron, L.; Avanzato, D.; Moccia, F.; Mancardi, D. Hydrogen sulfide as a regulator of calcium channels. Cell Calcium, 2013, 53(2), 77-84.
216. Li, L.; Whiteman, M.; Guan, Y. Y.; Neo, K. L.; Cheng, Y.; Lee, S. W.; Zhao, Y.; Baskar, R.; Tan, C. H.; Moore, P. K. Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137): new insights into the biology of hydrogen sulfide. Circulation, 2008, 117(18), 2351-2360.
217. Liu, Z.; Han, Y.; Li, L.; Lu, H.; Meng, G.; Li, X.; Shirhan, M.; Peh, M. T.; Xie, L.; Zhou, S.; Wang, X.; Chen, Q.; Dai, W.; Tan, C. H.; Pan, S.; Moore, P. K.; Ji, Y. Hydrogen sulfide donor, GYY4137, exhibits anti-atherosclerotic activity in high fat fed apolipoprotein E-/-mice. Br. J. Pharmacol., 2013, 169(8), 1795-1809.
218. Wingler, K.; Hermans, J. J.; Schiffers, P.; Moens, A.; Paul, M.; Schmidt, H. H. NOX1, 2, 4, 5: counting out oxidative stress. Br. J. Pharmacol., 2011, 164(3), 866-883.
219. Schulz, E.; Jansen, T.; Wenzel, P.; Daiber, A.; Münzel, T. Review Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid. Redox. Signal., 2008, 10(6), 1115-1126.
220. Bedard, K.; Krause, K. H. (2007). The NOX family of ROSgenerating NADPH oxidases: physiology and pathophysiology. Physiol. Rev., 2007, 87(1), 245-313.
221. Rodiño-Janeiro, B. K.; Paradela-Dobarro, B.; Castiñeiras-Landeira, M. I.; Raposeiras-Roubín, S.; González-Juanatey, J. R.; Alvarez, E. Current status of NADPH oxidase research in cardiovascular pharmacology. Vasc. Health Risk Manag., 2013, 9, 401-428.
222. Datla, S. R.; Griendling, K. K. Reactive oxygen species, NADPH oxidases, and hypertension. Hypertension, 2010, 56(3), 325-330.
223. Dikalova, A. E.; Bikineyeva, A. T.; Budzyn, K.; Nazarewicz, R. R.; McCann, L.; Lewis, W.; Harrison, D. G.; Dikalov, S. I. Therapeutic targeting of mitocondrial superoxide in hypertension. Circ. Res., 2010, 107(1), 106-116.
224. Matsuno, K.; Yamada, H.; Iwata, K.; Jin, D.; Katsuyama, M.; Matsuki, M.; Takai, S.; Yamanishi, K.; Miyazaki, M.; Matsubara, H.; Yabe-Nishimura, C. Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation, 2005, 112(17), 2677-2685.
225. Drummond, G. R.; Selemidis, S.; Griendling, K. K.; Sobey, C. G. Sobey. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nature Reviews Drug Discovery, 2011, 10(6), 453-471.
226. Wind, S.; Beuerlein, K.; Eucker T.; Müller, H.; Scheurer, P.; Armitage, ME.; Ho H.; Schmidt, H. H.; Wingler K. Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br. J. Pharmacol., 2010, 161(4), 885-898.
227. Cayatte, A. J.; Rupin, A.; Oliver-Krasinski, J.; Maitland, K.; Sansilvestri-Morel, P.; Boussard, M. F.; Wierzbicki, M.; Verbeuren, T. J.; Cohen, R. A. S17834, a new inhibitor of cell adhesion and atherosclerosis that targets NADPH oxidase. Arterioscler. Thromb. Vasc. Biol., 2001, 21(10), 1577-1584.
228. Sedeek, M.; Gutsol, A.; Montezano, A. C.; Burger, D.; Nguyen Dinh Cat, A.; Kennedy, C. R.; Burns, K. D.; Cooper, M. E.; Jandeleit-Dahm, K.; Page, P.; Szyndralewiez, C.; Heitz, F.; Hebert, R. L.; Touyz, R. M. Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes. Clin. Sci. (Lond)., 2013, 124(3), 191-202.
229. Gardner, D. G.; Chen, S.; Glenn, D. J.; Grigsby, C. L. Molecular biology of the natriuretic peptide system: implications for physiology and hypertension. Hypertension, 2007, 49(3), 419-426.
230. Hildebrandt, P.; Boesen, M.; Olsen, M.; Wachtell, K.; Groenning, B. N-terminal pro-brain natriuretic peptide in arterial hypertension - a marker for left ventricular dimensions and prognosis. Eur. J. Heart. Fail., 2004, 6(3), 313-317.
231. Newton-Cheh, C.; Larson, M. G.; Vasan, R. S.; Levy, D.; Bloch, K. D.; Surti, A.; Guiducci, C.; Kathiresan, S.; Benjamin, E. J.; Struck, J.; Morgenthaler, N. G.; Bergmann, A.; Blankenberg, S.; Kee, F.; Nilsson, P.; Yin, X.; Peltonen, L.; Vartiainen, E.; Salomaa, V.; Hirschhorn, J. N.; Melander, O.; Wang, T. J. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat. Genet., 2009, 41(3), 348-353.
232. Edelson, J. D.; Makhlina, M.; Silvester, K. R.; Vengurlekar, S. S.; Chen, X.; Zhang, J.; Koziol-White, C. J.; Cooper, P. R.; Hallam, T. J.; Hay, D. W.; Panettieri, R. A. Jr. In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo (Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH (2)) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidase and acts as a bronchodilator. Pulm. Pharmacol. Ther., 2013, 26(2), 229-238.
233. Li, Y.; Sarkar, O.; Brochu, M,; Anand-Srivastava, M. B. Natriuretic peptide receptor-C attenuates hypertension in spontaneously hypertensive rats: role of nitroxidative stress and Gi proteins. Hypertension., 2014, 63(4), 846-855.
234. Serafim, R. A.; Primi, M. C.; Trossini, G. H.; Ferreira, E. I. Nitric oxide: state of the art in drug design. Curr. Med. Chem., 2012, 19(3), 386-405.
235. Miller, M. R.; Megson, I. L. Recent developments in nitric oxide donor drugs. Br. J. Pharmacol., 2007, 51(3), 305-321.
236. Okuyama, C. E.; Mendes, G. D.; Faro, R.; Rezende, V. M.; Lagos, R. M.; Astigarraga, R. E.; Antunes, E.; De Nucci, G. Pharmacokinetics and pharmacodynamics of a nitric oxide-releasing derivative of enalapril in male beagles. Clin Exp. Pharmacol. Physiol., 2007, 34(4), 290-295.
237. Breschi, M. C.; Calderone, V.; Digiacomo, M.; Martelli, A.; Martinotti, E.; Minutolo, F.; Rapposelli, S.; Balsamo, A. NOsartans: a new class of pharmacodynamic hybrids as cardiovascular drugs. J. Med. Chem., 2004, 47(23), 5597-5600.
238. Li, Y. Q.; Ji, H.; Zhang, Y. H.; Shi, W. B.; Meng, Z. K.; Chen, X. Y.; Du, G. T.; Tian, J. WB1106, a novel nitric oxide-releasing derivative of telmisartan, inhibits hypertension and improves glucose metabolism in rats. Eur. J. Pharmacol., 2007, 577(1-3), 100-108.
239. Liao, J. K.; Laufs, U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol., 2005, 45, 89-118.
240. Ongini, E.; Impagnatiello, F.; Bonazzi, A.; Guzzetta, M.; Govoni, M.; Monopoli, A.; Del Soldato, P.; Ignarro, L. J. Nitric oxide (NO) - releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties. Proc. Natl. Acad. Sci. U. S. A., 2004, 101(22), 8497-8502.
241. ∗), 8a alpha]]-1, 2, 6, 7, 8, 8a-Hexahydro-beta, delta, 6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1-naphtaleneheptanoic acid 4-(nitrooxy) butyl ester)], reduces splenocyte adhesion and reactive oxygen species generation in normal and atherosclerotic mice. J. Pharmacol. Exp. Ther., 2007, 320(1), 419-426.
242. Momi, S.; Monopoli, A.; Alberti, P. F.; Falcinelli, E.; Corazzi, T.; Conti, V.; Miglietta, D.; Ongini, E.; Minuz, P.; Gresele, P. Nitric oxide enhances the anti-inflammatory and anti-atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis. Cardiovasc Res., 2012, 94(3), 428-438.
243. Lacer. Derivates of isosorbid mononitrate as vasodilator agents with reduced tolerance. Patent WO0020420, 2005.
244. Vilahur, G.; Segales, E.; Casani, L.; Badimon, L. A novel antiischemic nitric oxide donor inhibits thrombosis without modifying haemodynamic parameters. Thromb. Haemost., 2004, 91(5), 1035-1043.
245. Hernandez, M. R.; Tonda, R.; Arderiu, G.; Pino, M.; Serradell, M.; Escolar, G. Antithrombotic effect of a new nitric oxide donor (LA419) on experimental thrombogenesis. Eur. J. Clin. Invest., 2005, 35(5), 337-342.
246. Ruiz-Hurtado, G.; Fernandez-Velasco, M.; Mourelle, M.; Delgado, C. LA419, a novel nitric oxide donor, prevents pathological cardiac remodeling in pressure-overloaded rats via endothelial nitric oxide synthase pathway regulation. Hypertension, 2007, 50(6), 1049-1056.
247. Xu, J.; Li, G.; Wang, P.; Velazquez, H.; Yao, X.; Li, Y.; Wu, Y.; Peixoto, A.; Crowley, S.; Desir, G. V. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J. Clin. Invest., 2005, 115(5), 1275-1280.
248. Desir, G. V.; Wang, L.; Peixoto, A. J. Human renalase: a review of its biology, function, and implications for hypertension. J. Am. Soc. Hypertens., 2012, 6(6), 417-426.
249. Li, G.; Xu, J.; Wang, P.; Velazquez, H.; Li, Y.; Wu, Y.; Desir, G. V. Catecholamines regulate the activity, secretion, and synthesis of renalase. Circulation, 2008, 117(10), 1277-1282.
250. Desir, G. V. Role of renalase in the regulation of blood pressure and the renal dopamine system. Opin. Nephrol. Hypertens., 2011, 20, 31-36.
251. Wu, Y.; Xu, J.; Velazquez, H.; Wang, P.; Li, G.; Liu, D.; Sampaio-Maia, B.; Quelhas-Santos, J.; Russell, K.; Russell, R.; Flavell, R. A.; Pestana, M.; Giordano, F.; Desir, G. V. Renalase deficiency aggravates ischemic myocardial damage. Kidney Int., 2011, 79(8), 853-860.
252. Zhao, Q.; Fan, Z.; He, J.; Chen, S.; Li, H.; Zhang, P.; Wang, L.; Hu, D.; Huang, J.; Qiang, B.; Gu, D. Renalase gene is a novel susceptibility gene for essential hypertension: a two-stage association study in northern Han Chinese population. J. Mol. Med., 2007, 85(8), 877-885.
253. Farzaneh-Far R, Desir GV, Na B, Schiller NB, Whooley MA. A functional polymorphism in renalase (Glu37Asp) is associated with cardiac hypertrophy, dysfunction, and ischemia: data from the heart and soul study. PLoS One., 2010, 5(10), e13496.
254. Jiang, W.; Guo, Y.; Tan, L.; Tang, X.; Yang, Q.; Yang, K. Impact of renal denervation on renalase expression in adult rats with spontaneous hypertension. Exp. Ther. Med., 2012, 4(3), 493-496.
255. Baraka, A.; El Ghotny, S. Cardioprotective effect of renalase in 5/6 nephrectomized rats. J. Cardiovasc. Pharmacol. Ther., 2012, 17(4), 412-416.
256. Lee, H. T.; Kim, J. Y.; Kim, M.; Wang, P.; Tang, L.; Baroni, S.; D'Agati, V. D.; Desir, G. V. Renalase protects against ischemic AKI. J. Am. Soc. Nephrol., 2013, 24(3), 445-455.
257. Uehata, M.; Ishizaki, T.; Satoh, H.; Ono, T.; Kawahara, T.; Morishita, T.; Tamakawa, H.; Yamagami, K.; Inui, J.; Maekawa, M.; Narumiya, S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature, 1997, 389(6654), 990-994.
258. Somlyo, A. P.; Somlyo, A. V. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and nonmuscle myosin II. J. Physiol., 2000, 522(Pt 2), 177-185.
259. Shimokawa, H.; Takeshita, A. Rho-Kinase Is an Important Therapeutic Target in Cardiovascular Medicine. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005, 25(9), 1767-1775.
260. Wettschureck, N.; Offermanns, S. Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J. Mol. Med., 2002, 80(10), 629-638.
261. Liao, J. K.; Seto, M.; Noma, K. Rho kinase (ROCK) inhibitors. J. Cardiovasc. Pharmacol., 2007, 50(1), 17-24.
262. Loirand, G.; Pacaud, P. The role of Rho protein signaling in hypertension. Nature Reviews Cardiology, 2010, 7(11), 637-647.
263. Budzyn, K.; Marley, P. D.; Sobey, C. G. Targeting Rho and Rhokinase in the treatment of cardiovascular disease. Trends Pharmacol. Sci., 2006, 2(2), 97-104.
264. Doe, C.; Bentley, R.; Behm, D. J.; Lafferty, R.; Stavenger, R.; Jung, D.; Bamford, M.; Panchal, T.; Grygielko, E.; Wright, L. L.; Smith, G. K.; Chen, Z.; Webb, C.; Khandekar, S.; Yi, T.; Kirkpatrick, R.; Dul, E.; Jolivette, L.; Marino, J. P. Jr.; Willette, R.; Lee, D.; Hu, E. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J. Pharmacol. Exp. Ther., 2007, 320(1), 89-98.
265. Löhn, M.; Plettenburg, O.; Ivashchenko, Y.; Kannt, A.; Hofmeister, A.; Kadereit, D.; Schaefer, M.; Linz, W.; Kohlmann, M.; Herbert, J. M.; Janiak, P.; O'Connor, S. E.; Ruetten, H. Pharmacological Characterization of SAR407899, a Novel Rho-Kinase Inhibitor. Hypertension, 2009, 54(3), 676-683.
266. Liu, G. J.; Wang, Z. J.; Wang, Y. F.; Xu, L. L.; Wang, X. L.; Liu, Y.; Luo, G. J.; He, G. H.; Zeng, Y. J. Systematic assessment and metaanalysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage. Eur. J. Clin. Pharmacol., 2012, 68(2), 131-139.
267. Higashi, M.; Shimokawa, H.; Hattori, T.; Hiroki, J.; Mukai, Y.; Morikawa, K.; Ichiki, T.; Takahashi, S.; Takeshita, A. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo. Effects on endothelial NAD (P) H oxidase system. Circ. Res., 2003, 93(8), 767-775.
268. Campbell, W. B.; Fleming, I. Epoxyeicosatrienoic acids and endothelium-dependent responses. Pflügers Arch., 2010, 459(6), 881-895.
269. Imig, J. D.; Hammock, B. D. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat. Rev. Drug. Discov., 2009, 8(10), 794-805.
270. Sudhahar, V.; Shaw, S.; Imig, J. D. Epoxyeicosatrienoic acid analogs and vascular function. Curr Med Chem., 2010, 17, 1181-1190.
271. Watanabe H, Vriens J, Prenen J, Droogmans G, Voets T, Nilius B. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature, 2003, 424, 434-438.
272. Anandan, S. K.; Webb, H. K.; Chen, D.; Wang, Y. X.; Aavula, B. R.; Cases, S.; Cheng, Y.; Do, Z. N.; Mehra, U.; Tran, V.; Vincelette, J.; Waszczuk, J.; White, K.; Wong, K. R.; Zhang, L. N.; Jones, P. D.; Hammock, B. D.; Patel, D. V.; Whitcomb, R.; MacIntyre, D. E.; Sabry, J.; Gless, R. 1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia. Bioorg. Med. Chem. Lett., 2010, 21(3), 983-988.
273. Zhang, L. N.; Vincelette, J.; Chen, D.; Gless, R. D.; Anandan, S. K.; Rubanyi, G. M.; Webb, H. K.; MacIntyre, D. E.; Wang, Y. X. Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension. Eur. J. Pharmacol., 2011, 654(1), 68-74.
274. Imig, J. D.; Carpenter, M. A.; Shaw, S. The soluble epoxide hydrolase inhibitor AR9281 decreases blood pressure, ameliorates renal injury and improves vascular function in hypertension. Pharmaceuticals, 2009, 2(3), 217-227.
275. Jiang, H.; Quilley, J.; Doumad, A. B.; Zhu, A. G.; Falck, J. R.; Hammock, B. D.; Stier, C. T. Jr.; Carroll, M. A. Increases in plasma trans-EETs and blood pressure reduction in spontaneously hypertensive rats. Am. J. Physiol. Heart. Circ. Physiol., 2011, 300(6), H1990-H1996.
276. Gross, G. J.; Gauthier, K. M.; Moore, J.; Falck, J. R.; Hammock, B. D.; Campbell, W. B.; Nithipatikom, K. Effects of the selective EET antagonist, 14, 15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am. J. Physiol. Heart. Circ. Physiol., 2008, 294(6), H2838-H2844.
277. Seubert, J. M.; Zeldin, D. C.; Nithipatikom, K.; Gross, G. J. Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid. Mediat., 2007, 82(1-4), 50-59.
278. Luo, P.; Chang, H. H.; Zhou, Y.; Zhang, S.; Hwang, S. H.; Morisseau, C.; Wang, C. Y.; Inscho, E. W.; Hammock, B. D.; Wang, M. H. Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. J. Pharmacol. Exp. Ther., 2010, 334(2), 430-438.
279. Chen, D.; Whitcomb, R.; MacIntyre, E.; Tran, V.; Do, Z. N.; Sabry, J.; Patel, D. V.; Anandan, S. K.; Gless, R.; Webb, H. K. Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects. J. Clin. Pharmacol., 2012, 52(3), 319-328.
280. Loot, A. E.; Fleming, I. Cytochrome P450-derived epoxyeicosatrienoic acids and pulmonary hypertension: central role of transient receptor potential C6 channels. J. Cardiovasc. Pharmacol., 2011, 57(2), 140-147.
281. Loot, A. E.; Moneke, I.; Keserü, B.; Oelze, M.; Syzonenko, T.; Daiber, A.; Fleming, I. 11, 12-EET stimulates the association of BK channel α and β (1) subunits in mitochondria to induce pulmonary vasoconstriction. PLoS One, 2012, 7(9), e46065.
282. Evgenov, O. V.; Pacher, P.; Schmidt, P. M.; Haskó, G.; Schmidt, H. H.; Stasch, J. P. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat. Rev. Drug. Discov., 2006, 5(9), 755-768.
283. Tamargo, J.; Duarte, J.; Caballero, R.; Delpón, E. Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure. Curr. Opin. Investig. Drugs, 2010, 11(9), 1039-1047.
284. Stasch, J. P.; Becker, E. M.; Alonso-Alija, C.; Apeler, H.; Dembowsky, K.; Feurer, A.; Gerzer, R.; Minuth, T.; Perzborn, E.; Pleiss, U.; Schröder, H.; Schroeder, W.; Stahl, E.; Steinke, W.; Straub, A.; Schramm, M. NO-independent regulatory site on soluble guanylate cyclase. Nature, 2001, 410(6825), 212-215.
285. Masuyama, H.; Tsuruda, T.; Kato, J.; Imamura, T.; Asada, Y.; Stasch, J.; Kitamura, K.; Eto, T. Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin ii-induced hypertensive rats. Hypertension, 2006, 48(5), 972-978.
286. Hobbs, A. J. Soluble guanylate cyclase: an old therapeutic target revisited. Br. J. Pharmacol., 2002, 136(5), 637-640.
287. Stasch, J. P.; Schmidt, P. M.; Nedvetsky, P. I.; Nedvetskaya, T. Y.; HńS, A. K.; Meurer, S.; Deile, M.; Taye, A.; Knorr, A.; Lapp, H.; Müller, H.; Turgay, Y.; Rothkegel, C.; Tersteegen, A.; Kemp-Harper, B.; Müller-Esterl, W.; Schmidt, H. H. Targeting the hemeoxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J. Clin. Invest., 2006, 116(9), 2552-2561.
288. Stasch, J. P.; Schmidt, P.; Alonso-Alija, C.; Apeler, H.; Dembowsky, K.; Haerter, M.; Heil, M.; Minuth, T.; Perzborn, E.; Pleiss, U.; Schramm, M.; Schroeder W.; Schroder, H.; Stahl, E.; Steinke, W.; Wunder, F. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br. J. Pharmacol., 2002, 136(5), 773-783.
289. Gheorghiade, M.; Greene, S. J.; Filippatos, G.; Erdmann, E.; Ferrari, R.; Levy, P. D.; Maggioni, A.; Nowack, C.; Mebazaa, A.; COMPOSE Investigators and Coordinators. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur. J. Heart Fail., 2012, 14(9), 1056-1066.
290. Erdmann, E.; Semigran, M. J.; Nieminen, M. S.; Gheorghiade, M.; Agrawal, R.; Mitrovic, V.; Mebazaa, A. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur. Heart J., 2013, 34(1), 57-67.